Literature DB >> 14667104

Systemic lupus erythematous with recurrent Guillain-Barré-like syndrome treated with intravenous immunoglobulins.

M Lewis1, T Gibson.   

Abstract

We report on an unusual case of a young African male with systemic lupus erythematosus who developed an acute, severe Guillain-Barré-like peripheral neuropathy associated with ascites. The illness appeared to respond dramatically to a short course of intravenous immunoglobulins. Eight months later he had recurrence of identical features. He required respiratory support. On this occasion there was no response to intravenous immunoglobulins or other measures and he died of sepsis after a protracted period of paralysis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14667104     DOI: 10.1191/0961203303lu464cr

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  5 in total

Review 1.  Intravenous immunoglobulin therapy and systemic lupus erythematosus.

Authors:  Gisele Zandman-Goddard; Yair Levy; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 2.  Intravenous immunoglobulin treatment in vasculitis and connective tissue disorders.

Authors:  Andreas Steinbrecher; Peter Berlit
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

3.  Fulminant Guillain-Barré syndrome in a patient with systemic lupus erythematosus.

Authors:  Eric Anthony Coomes; Hourmazd Haghbayan; Jenna Spring; Sangeeta Mehta
Journal:  BMJ Case Rep       Date:  2019-01-14

Review 4.  Glucocorticoid-Induced Myopathy in a Patient with Systemic Lupus Erythematosus (SLE): A Case Report and Review of the Literature.

Authors:  Elliot M Silver; William Ochoa
Journal:  Am J Case Rep       Date:  2018-03-11

5.  Systemic Lupus Erythematosus With Acute Inflammatory Demyelinating Polyneuropathy: A Case Report and Review of the Literature.

Authors:  Xiangling Li; Yanqiang Wang
Journal:  J Clin Med Res       Date:  2016-05-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.